
Moderna soars on analyst upgrade
Published on January 3, 2024
Moderna's stock surges on positive analyst outlook, reflecting the potential of its innovative mRNA-based vaccines and therapies.

Moderna's stock surges on positive analyst outlook, reflecting the potential of its innovative mRNA-based vaccines and therapies.